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Hematopoietic growth factors have now been purified, cloned, and produced in bacteria and
yeast. Those that are currently in clinical study include erythropoietin, GM-CSF, G-CSF,
M-CSF (also called CSF-1), and multi-CSF (also called interleukin 3). Growth factors appear
likely to enhance the recovery and function ofcirculating white cells after standard-dose cancer
therapy and high-bone-dose cancer therapy with marrow transplant and to restore leukocyte
numbers and competence in the acquired immune deficiency syndromes and myelodysplastic
syndromes. Phase I, II trials in AIDS, in cancer patients receiving chemotherapy, in cases of
myeloproliferative disease, and after bone marrow transplant have been published. The results of
phase III studies arejust becoming available.
REGULATION OF NORMAL WBC PROLIFERATION AND FUNCTION
In Vitro Studies
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a major hor-
monal regulator of human granulopoiesis [1,2,3]. GM-CSF enhances both prolifera-
tion ofmyeloid precursor cells and the function ofmature peripheral blood neutrophils
and mononuclear phagocytes. (Refer to Table 1.) GM-CSF is a protein that acts in
picomolar concentrations to stimulate colonies of differentiated granulocytes and
monocytes insemisolid media [3,13]. Complementary DNA clonesencoding GM-CSF
have been isolated, and recombinant human (rh) GM-CSF produced [13]. This
material possesses biologic activity for the development ofgranulocytes, mixed granu-
locyte-macrophage, pure eosinophil, and multipotent mixed cell progenitor colonies
from both normal bone marrow and human myeloid leukemia cell lines, HL-60 and
KG-I [14,15]. GM-CSF also stimulates thegrowth ofhuman erythroid burst-forming
units (BFU-E) in the presence oferythropoietin when adherent and E-rosette forming
cells areremoved from preparations [14,16]. GM-CSFis a weakbutconsistentinducer
of differentiation in HL-60 cells, resulting in increased numbers of cells displaying
monocytic and eosinophilic characteristics [15].
GM-CSF has neutrophil migration-inhibition activity and has been previously
described as a neutrophil migration-inhibition factor from T-lymphoblast cell lines
[3,17]. In functional studies, GM-CSF stimulates superoxide anion generation in
response to the bacterial chemoattractant, N-formyl-methionyl-leucyl-phenylalanine
[17]. Thus, GM-CSF stimulates growth of myeloid precursor cells and augments
neutrophil oxidative metabolism important in neutrophil microbicidal and tumoricidal
activities [16].
GM-CSF induces cellular activities after binding with specific high-affinity recep-
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TABLE 1
Laboratory Studies with Clinical Implications ofG- or GM-CSFon Granulocyte Function
First
Author No. Observation Reference
Baldwin Produces functionally active PMNs [4]
Mayani Greater response ofmyeloid cells [5]
Socinski Greater CDl lbcell surfaceprotein [6]
Sullivan Greater acidity within PMN [7]
Sullivan 7 Greater granulocyte superoxide generation after in vitro stimulation [8]
Peters Fluid migration into a sterile field (skin window response) [9]
Linch 4 Skin window responses present in two ofthree patients [10]
Addison 8 Skin window responses fluid 30 percent in four ofnine patient studies [ 11]
Tobler Vitamin D decreases GM-CSF production [12]
No., number ofpatients studied
tors on the plasma membrane of responding granulocytes and macrophages. Specific
binding to high-affinity saturable cell surface receptors occurred on two human cell
lines that exhibit proliferative responses to GM-CSF (KG-1, an acute myelocytic
leukemia [AML] cell line, and HL-60, a promyelocytic cell line.)
Thus, granulocytes exposed to granulocyte colony-stimulating factor (G-CSF) or
GM-CSF appear to be primed for activation and more efficient in killing bacteria. In
some patients, migration into a sterile skin window appears to be suboptimal after
GM-CSF but not during G-CSF administration.
In Vivo Primate Studies
Recombinant human (rh) GM-CSF, administered intravenously (iv) or subcutane-
ously over seven to 30 days to non-human primates [18], have demonstrated dose-
dependent increases in total peripheral whiteblood cell (WBC) counts (predominantly
increases in the absolute numbers of mature neutrophils, neutrophilic basophils, and
eosinophils, with less consistent increases in platelets andoccasionally lymphocytes).
Depending upon the method of administration, the total peripheral WBC has
increased as early as 48 to 72 hours after beginning administration of GM-CSF,
associated with bone marrow hyperplasia of the appropriate cell lines. In one study,
peripheral blood neutrophils obtained during treatment with GM-CSF exhibited
morphologic and functional changes associated with cellular priming for activation
(increased superoxide anion generation and enhanced phagocytosis of opsonized E.
coli).
With theexception ofcutaneousflushing insomeanimals, feverinoneanimalduring
and immediately after administration, and the development of specific antibodies to
human GM-CSF, no clinically significant adverse reactions were noted in any of the
non-human primate studies. Doses ranged from 2-176 ,g/kg/day of protein (4-300
,ug/kg/day of glycoprotein) equivalent to 0.06-7.2 x 105 units/kg/day of activity
(measured as the stimulation of 3H-thymidine uptake by peripheral blood cells from
patients with chronic myelocytic leukemia [CML].
Dose-response was evaluated by administration of 0 (vehicle only), 5, 15, 30, or 60
,tg/kg GM-CSF (twoorthreeanimals perdoselevel) twice aday intravenous bolus for
fiveconsecutivedays. Significant increases in WBC counts wereobserved in all animals
within one week, with the maximal WBC observed at 15 ag/kg. Both subcutaneous
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TABLE 2
CSFs Currently Undergoing Clinical Trials
Phase I
Phase II
Factor Company Produced in Institution Dose,ug/Day Schedule Dose
GM-CSF Sandoz CHO Duke 2-32/kg 24-hour CI <32
DFCI 4-64/kg 24-hour CI <32
NEDH .3-45/kg 24-hour CI <32
GM-CSF Schering E. coli Christie 3-10/kg 24-hour CI
GM-CSF Immunex Yeast MDAH 30-500/m2 24-hour CI 30
C-CSF AmGen E. coli MSKCC 1-60/kg 30 minutes daily
Manchester 1-10/kg 24-hour CI
UCLA 1-6/kg Subcutaneous daily
MDAH 1-3/kg Subcutaneous daily
G-CSF Kirin E. coli Tokyo 50-1,600/M2
DFCI: Dana-Farber Cancer Institute
MDAH: M.D. Anderson Hospital, Houston
MSKCC: Memorial Sloan-Kettering Cancer Center, New York City
NEDH: New England Deaconess Hospital
UCLA: University ofCalifornia, Los Angeles
and intravenous administration resulted in comparable increases in WBC count.
(Refer to Table 2.)
The optimal schedule ofGM-CSF seems to be 5 ,tg/kg/day subcutaneously twice a
day. Intravenous bolus schedules areassociated with poor efficacy. High peaklevels are
associated with shortness of breath at the initial treatment. Higher doses result in an
increased incidence ofpericarditis [19,20].
LEUKEMIA
Growth factors are being studied as agents to synchronize leukemic cells in patients
with refractory acute myelocytic leukemia (AML) prior to high-dose cytarabine [21].
In other studies, GM-CSF is being given after reinduction therapy in refractory
patients [22] or in newly diagnosed AML patients at high risk [22,23] in order to
attempt to decrease the period of aplasia. One patient treated with GM-CSF for
idiopathic neutropenia normalized his WBC and was found to have hairy cell leukemia
[24]. (Refer to Table 3.)
The results ofclinical trials so far suggest that GM-CSF should enhance theactivity
of a phase-specific cytotoxic drug against AML. In subsets of patients with AML,
G- and GM-CSF result in an earlier than expected recovery compared to historical
controls. Whether the fraction of AML patients who have regrowth of leukemic cells
after induction is increased by treatment with GM-CSF or G-CSF is not known. One
randomized trial of 98 patients describes a significantly shorter recovery after induc-
tion treatment, significant decrement in the number of infections, and a complete
response rate of 50 percent in the group receiving GM-CSF (versus 38 percent
complete responses in the group randomized to placebo). G-CSF alone and with
interferon has been used in patients with hairy cell leukemia and neutropenia with
substantial increases in granulocyte count. The white count in one patient treated with
GM-CSF for a diagnosis of aplastic anemia increased from 1,700 to 5,600 with the
appearance ofhairy cells (presumably the etiology ofhis prior neutropenia).
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TABLE 3
CSF Studies in Leukemia
First Author Response Reference
Laboratory
Ciaiolo GM-CSFenhances methotrexate cytotoxicity [25]
Cannistra GM-CSFenhances cytarabine cytotoxicity [21]
First Dose
Author No. Mg/Day Response Reference
Clinical
GMCSF
Zuehlsdorf 24 Shortened aplasia; 3 with AML regrowth [22]
Estey 12 120/m2 4died, 6 CRs; "4 earlier than expected recovery"; 1 APML re- [23]
growth
Schuster 1 3/kg Rxfor "AA"; WBC 1.7 to 5.6; hairy cells [24]
Gattringer 8 10/kg 1/8 relapsed after a delay [26]
G-CSF
Glaspy 4 1-6, g/kg PMN in 3/4 with hairy cell/neutropenia <900 to >4,000/Ml [27]
Glaspya 6 3-6 Mg/kg PMN in 5/5 with hairy cell/enutropenia <827 to >6,856/,ul [28]
Ohnoa 98 200/M2 Significantly shorter recovery, infections 5 versus 15 percentCR [29]
50versus 38 percent
Teshima 8 50-200/M2 ANC recovery in <10 days [30]
aWith interferon
AA: aplastic anemia
APML: acute promyelocytic leukemia
CR: complete response
APLASTIC ANEMIA
In aplastic anemia, the number of patients with WBCs "responding" to GM-CSF
has ranged from one in four patients to ten of 11. Increased white counts ranged from
1.6- to tenfold increase in improvement. In the only randomized trial, a small study of
seven patients, the four patients randomized to GM-CSF responded. The three control
patients alsoresponded when they werecrossed over after failure torespond toplacebo.
(Refer to Table 4.)
MYELODYSPLASIA
Significantly increased leukocytes,granulocytes, monocytes, lymphocytes, andeosino-
phils were observed (as well as platelets and reticulocytes in a few) in patients treated
with GM-CSF generally for at least two weeks. Toxicity includes bone pain as well as
sporadic fever, chills, myalgias, headache, and anorexia. (Refer to Table 5.)
In laboratory studies ofgranulocytes from patients with myelodysplasia, G-CSFand
GM-CSFstimulated proliferation; however, the percentage ofblasts decreased in most
cases because of the increased absolute number of granulocytes. In clinical studies,
one-halfto three-quarters ofthe patients exhibited an improvement in white blood cell
count response, but 10 percent to 25 percent ofthe patients had an increased absolute
number of peripheral blood blasts. To attempt to decrease the risk of leukemic
transformation, some investigators have added low-dose cytarabine during the GM-
CSF infusion. In one randomized study of 48 patients, 27 of 28 patients responded to
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TABLE 4
CSF Studies in Aplastic Anemias
First Dose
Author Institution No. gg/Day WBC Response Reference
Nissin 4 4-32/kg In 1/4 patients [31]
Vadhan MDAH 10 60-500/M2 ft1.6-10 times [32, 33]
Antin BWH 15 15-480/m2 In 6/8 patients [34]
Champlin UCLA 15 4-64/kg In 1O/1 evaluable patients [35]
Rifkin Arizona 16 15-960/M2 Mean 8.5 times [36]
Schustera N Shore 7 3/kg 4/7 (failures crossed over) [37]
'Randomized
BWH: Brigham and Women's Hospital
MDAH: M.D. Anderson Hospital, Houston
N Shore: North Shore Hospital, New York
UCLA: UniversityofCalifornia, LosAngeles
GM-CSF. One patient each in the GM-CSF group and the placebo group developed
leukemia.
IDIOPATHIC NEUTROPENIA/AGRANULOCYTOSIS
Growth factors used in patients with various neutropenias (idiopathic, cyclic, and
congenital) seem responsive to even long-term useofG-CSF. Patients treated for three
to 15 months continue to respond with significantly increased granulocytes and
resolution ofprior infection. (Refer toTable 6.)
SOLID TUMORS
There are a number of studies of GM-CSF with and without chemotherapy.
Pharmacokinetic studies suggest that efficacy correlates with dose and area under the
curve. Subcutaneous administration appears to avoid some toxicities associated with iv
administration. In animal models, both G- and GM-CSF increase speed of recovery
after common cytotoxicdrugs. Laboratory studies havesuggested that a few fresh solid
tumors and cell lines are moderately stimulated by GM-CSF; however, more are
distinctly inhibited, and most were unaffected. There are now anecdotes of patients
with malignancy-associated leukemoid reactions found to have high serum growth
factor level, presumably oftumor origin.
A number ofinvestigators havedelivered GM-CSF alone (with nochemotherapy) in
order toattempt tomodulate monocytefunction. One sarcoma has partially responded.
Since there have been over 100 patients entered in such studies, the significance ofthis
response is difficult to assess. (Refer to Table 7.)
Multiple studies of G- and GM-CSF after chemotherapy for specific tumors or
miscellaneous malignancies suggest a decreased duration of neutropenia with either
growth factor. GM- or G-CSF without chemotherapy generally results in a dose-
dependent rise in WBC and granulocytes (to >20,000 WBC in a mean of four days).
The WBC nadir after chemotherapy is generally significantly shallower and shorter
than after historical controls. The total duration ofgranulocytopenia (polymorphonu-
clear leucocyte [PMN] <500/,ul) is generally significantly shorter. Fever occurs in
about halfthe patients receiving GM-CSF, and arthralgias, mild headaches, and skin
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TABLE 5
CSF Studies in Myelodysplasia
First Author Response Reference
Laboratory
Tohyama GM-CSF stimulated proliferation but decreased the percentage
ofblasts in 5/6 cases [38]
Carlo CFU-GM growth was markedly improved in 15/16 patients [39]
First Dose WBC
Author Institution No. gg/Day Response f Blasts Reference
Clinical
Antin BWH 15 15-480/M2 5/7 patients 2/7 [34]
Ganser Frankfurt 11 15-150/M2 10/11 4/11 [40, 41]
Vadhan MDAH 8 30-500/M2 0/8 [42]
Vadhan MDAH 1 "Complete 0/1 [43]
response"
Gradishar Chicago 9 60-500/m2 7/8 evaluable 3/9 (+3 lymphoma) [44]
patients
Thompson Seattle 16 .3-10/kg 11/13 1/16 [45]
Hoffkena Essen, FRG 12 250/M2 5/12 2/12 [46]
Gansera Frankfurt 5 250/M2 3/5 0/5 [47]
Herrmann 4 Varied 4/4 At doses >500/M2 [48]
Hoelzera Frankfurt 10 15-150/M2 9/10; 1 inc "Some"; IF LD ara-C [49]
platelets
Schuster' N Shore 48 3/kg 27/28 1/28; 2/48 [37]
G-CSF
Kobayashi Tokyo Kirin 4 50-1,600/M2 4/4 Two to three [50]
times in BM
Negrin Stanford AmGen 12 .1-3/kg 10/12 five Transiently [51]
times
f PMN
'Plus low-dose cyarabine
bRandomized
BWH: Brigham and Women's Hospital
FRG: Federal Republic ofGermany
MDAH: M.D. Anderson Hospital, Houston
N Shore: North Shore Hospital, New York
rash in many patients at doses of 4-32 mg/kg/day. A syndrome of transient hypoxia
and neutropenia immediately after the first dose of GM-CSF results from increased
granulocyte adhesion proteins (CD11b) andcongregation ofgranulocytes in the lungs.
At high doses (e.g., 64 mg/kg/day), however, thromboses around central lines,
pulmonary emboli, and 5-10 kg weight gain associated with pleural and pericardial
effusions (capillary leak syndrome) as well as atrial arrhythmias have been reported.
Morstyn et al. [93] reported a study of a sequence of schedules of G-CSF after 25
mg/mi2 of Melphalan. Occasional bone discomfort was the only side effect. G-CSF
could be started as late as eight after chemotherapy and did not need to be continued
more then seven days [94].
Randomized trials are nowjust being reported, including a study by Crawford et al.
[83] including 126 patients with small-cell lung cancer treated with repeated cycles of
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TABLE 6
CSF Studies in Neutropenia
Author No. Response Reference
Laboratory
Wright 4 Stimulation ofCFU-GM required ten times [52J
GM-CSF than normals
Dose
First Author Institution Product No. Mg/Day WBC Response Reference
Clinical
GM-CSF
Ganser Frankfurt Immunex 4 150-1,000/M2 ft in 4/4; resolution of [53]
infection
G-CSF
Congenital
agranulocytosis
Bonilla MSKCC AmGen 5 3-60/kg 5/5 PMN <100 to 1,300-9,500/ [54]
,Ml 9-13 months
Cyclic neutropenia
Hammond Seattle AmGen 6 3-10/kg Nadir PMN 17/,Ml to [55]
1,393/Ml; 3-15 months
Chronic idiopathic
neutropenia
Jakubowski MSKCC AmGen 1 1-3/kg PMN 40/1l to >1,500A/I [56]
MSKCC: Memorial Sloan-Kettering Cancer Center, New YorkCity
cyclophosphamide, adriamycin, and etoposide with significant differences in duration
ofneutropenia, infections, and hospital days. A smaller randomized study from Osaka
draws similar conclusions.
BONE MARROW TRANSPLANTATION
Myelosuppression is the dose-limiting toxicity for many chemotherapy regimens;
however, for many tumors, optimum response cannot be achieved without exceeding
the dose of chemotherapeutic agents, which causes unacceptable myelosuppression.
Theconcept ofremoval and storageofsufficient numbers ofhematopoietic stem cells to
re-establish normal marrow function is well established in both animal models and
many human trials. In tumors such as lymphomas and Hodgkin's disease, high-dose
chemotherapy withautologous marrow "rescue" appears toresult in prolongeddisease-
free survival, compared to treatment with standard chemotherapy regimens for
patients failing standard therapy. The role of autografting in solid tumors is less well
defined at present, but considerable laboratory and clinical evidence suggests that sen-
sitivebutincurable tumors areappropriateforinvestigation ofhigh-dosechemotherapy.
The major morbidity of high-dose chemotherapy results from myelosuppression.
While anemia and thrombocytopenia can be treated by transfusion, no effective
method restores granulocyte and monocyte-macrophage levels. The incidence of
bacterial and fungal infection correlates with both duration and severity of neutrope-
nia. The first polymorphonuclear leucocyte (PMN) appears on complete blood counts
obtained on day 9 to 11. An absolute neutrophil count (ANC) >500 is achieved at a
median of 18 to 26 days after transplant with platelet transfusion independence at a
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TABLE 7
CSF Studies in Malignancy
First Author No. Response Reference
Laboratory Trials
Efficacy
Cebon 33 GM-CSF in humans: Efficacy a dose, AUC; [19]
SQ > IV. Toxicity adose.
O'Reilly GM-CSF in primates: Rapid WBC recovery after 5 FU [57]
Ono G-CSF in mice: Rapid WBC recovery after cyclophosphamide [58]
Effect ofGM-CSFon tumor (fresh orcelllines)
Dedhar ft growth, 2 osteosarcomas, 1 breast, fibroblasts [59]
Salmon 33 19, stable; 10, growth inhibition (marked in 3); [60]
4, moderate stimulation
Ohwade 1 A patient with 71,300 WBC and prostate cancer had [61]
serum G-CSF levels three times normal
Monocytefunction
Wing f monocyte numbers and function (cytotoxicity, TNF, IF) [62]
Kleinerman GM-CSF increases monocyte numbers; activated for tumor ly- [63]
sis in 1/7
No IL-I or TNF production
Cannistra GM-CSF increased tumor lysis after in vivo exposure [64]
Dose
First Author Institution No. ,ug/Day Tumor Observations Reference
Clinical Trials
GM-CSFalone (no chemotherapy)
Antman DFCI 16 4-64/kg Sarcomas [65]
Avashia Cleveland 13 60-250/m2 Lung Monocyte modulation [66]
Phillips 10 100-500/m2 Miscellaneous [67]
Steward 20 .3-60/kg Miscellaneous 1PR sarcoma; 7 SD [68]
Wing 100-500/m2 Refractory [62]
Linch 4 Miscellaneous Kinetic/skin window studies [10]
Lieschke Melbourne 21 .3-30/kg Miscellaneous [69]
Herrmann 30 120-1,000/m2 Miscellaneous No responses [70]
Aglietta 9 8/kg Miscellaneous $ S phase bone marrow [71]
cells after drug dcd
Hoogmoed NYU 16 30-150/m2 Refractory 8 patients> four timesmonocyte [72]
cytotoxicity
First Dose Refer-
Author Institution No. ug/Day Tumor Drugs ence
GM-CSFwith chemotherapy
Gerhartz' Munich 40 2-32/kg
Ajani MDAH 20 250-500/M2
Antman DFCI 16 4-64/kg
Rusthoven Ontario 7 10/kg
Fox Melbourne
Neidhart New Mexico 23 250-1,000/M2
Shea San Diego 12 5-10/kg
Speyer NYU 9 15/kg
Stitt Wisconsin 8
Hartmannb Mayo Clinics 33 10-20/kg
Gattringer 5 10/kg
Lowenberg Rotterdam 216 mg/bid
Lymphoma+
Esophagus
Sarcomas
Ovarian
Miscellaneous
Miscellaneous
Miscellaneous
Miscellaneous
Miscellaneous
Miscellaneous
Miscellaneous
Miscellaneous
Chemotherapy
VP-16, ADR, DDP
ADR, Ifos, DTIC
CPA, 400-800 carboplatin
(CBDCA and VP-16) x 3
CPA, VP-16, DDP
HD carboplatin
50-72 mg/m2 ADR
HDCPA, VP-16, DDP
1 gm CPA, 225-600 CBDCA
Miscellaneous
Repeated cycles
[73]
[74]
[65]
[75]
[76]
[77]
[78]
[79]
[20]
[26]
[80]
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TABLE 7-Continued
First Dose Refer-
Author Institution No. Ag/Day Tumor Drugs ence
G-CSF
Bronchud Manchester 12 1-40/kg SCLC [81,82]
Crawforda Duke 126 SCLC CPA, ADR, VP-16 [83]
Eguchi NCC, Tokyo 39 50-800/m2 Lung Miscellaneous [84]
Ogawara' Osaka 60 75/kg Lung Miscellaneous [85]
Takada Osaka 40 2/kg NSCLC Mit C, VDS, DDP [86]
Toki Japan 4 2/kg Lymphoma CHOP [87]
Ema Japan 4 100-800/M2 Lymphoma Miscellaneous [88]
Bronchud Manchester 17 10-5/kg Breast, ovary ADR [89]
Gabrilove MSKCC 27 1-60/kg Bladder Methotrexate, ADR, [90,91]
VBL, DDP
Fukutani JCF, Tokyo 17 25-800/m2 Miscellaneous Miscellaneous [92]
Morstyn Melbourne 15 1-60/kg Miscellaneous Melphalan [93]
Morstyn Melbourne 22 .3-10/kg Miscellaneous Melphalan [94]
Neidhart New Mexico Miscellaneous CPA, VP-16, DDP [95]
Stitt Wisconsin 13 60/kg Miscellaneous HDCPA, VP-16, DDP [79]
aRandomized
b5/33 patientsdeveloped atrial fibrillation while receiving GM-CSF at the highest dose level.
ADR: adriamycin
CBDCA: carboplatin
CPA: cyclophosphamide
DFCI: Dana-Farber Cancer Institute
DDP: cisplatin
DTIC: dacarbazine
HDCPA: high-dosecyclophosphamide
IF: interferon
Ifos: ifosfamide
IL-1: interleukin 1
JCF: Japan Cancer Foundation
MDAH: M.D. Anderson Hospital, Houston
MSKCC: Memorial Sloan-Kettering Cancer Center, New York City
NCC: National Cancer Center
NYU: New York University, New YorkCity
TNF: tumor necrosis factor
VBL: vinblastine
VDS: vindesine
VP-16: etoposide
median of21 to 28 days. A median of30 to 50 inpatient days is required for autologous
bone marrow transplant (ABMT). The psychological effect ofprolonged isolation and
hospitalization and hospital costs are substantial. The major cause ofthe 4-25 percent
mortality for ABMT remains infection or bleeding during the three- to four-week
period of profound myelosupression. More rapid hematologic reconstitution would
substantially reduce mortality, morbidity, and the expense ofhigh-dose therapy.
GM-CSF levels have been found to be elevated between days 7 and 21 after bone
marrow reinfusion, and increased serum levels are also measured in patients with
graft-versus-host disease (GVHD). Transient cyclic neutropenia has been reported
following the use of GM-CSF after an allograft for chronic granulocytic leukemia
(CGL). (Refer to Table 8.)
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TABLE 8
CSF Studies in Bone Marrow Transplantation
First
Author Response Reference
Laboratory
Yamasaki ABMT:GM-CSF in produced day 7-21 [96]
Kanamaru ft Serum levels ofGM-CSF produced in GVHD [97]
Atkinson Monokines recover early; lymphokines late [98]
Meagher Growth factors affect marrow cells in long-term culture [99]
Gluckman Transient cyclic neutropenia following GM-CSF after [100]
AlloBMT for CGL
Haas GM-CSF in long-term marrow culture expands neutrophil [101]
progenitors
Geissler Growth factor levels initially fall, then rise, peaking at day 8-14 [102]
Days to PMN > 500
GM-CSF Institution No. GM-CSF Control Reference
Clinical
Historical Controls
Brandt Duke 19 16 19 [103]
Nemunaitis Seattle 15 14 25 [104]
Blazer Minnesota 25 24 23 [105]
Herrmann Mainz 28 "Significant difference"
Link Hanover, FRG 11 14 20 [106]
Linkesch Vienna 4 15 24 [107]
Michon Paris 21 18 26 [108]
Lazarus Cleveland 12 14 22 [109]
Devereaux London 12 18 25 [110]
Response
First Author Institution No. Yes No Reference
PoorGraft Function
Klingeman Vancouver 9 6 3 [111]
Nemunaitis Seattle 37b 21 1 b [112]
Vose Nebraska 12 9 3 [113]
Randomized
Philipa Lyon 20 [114]
Nemunaitisa Seattle 30 16 17 [115]
Days to PMN > 500
G-CSF Institution No. G-CSF Control Reference
Historical Controls
Masaoka Japan 13 21 Significantly longer [116]
Mukaiyama Japan 10 "Significant difference" [117]
Teshima Japan 7 11 27 [30]
Sheridan Melbourne 15 11 20 [118]
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TABLE 8-Continued
Response
First _ _ _ _ _ _ _ _ _ _ _ _
Author Institution No. Yes No Reference
Poor Graft Function
Takaue Japan 1 1 [119]
Randomized
Masaokaa Japan 66 "Significant difference" [120]
aRandomized
bIncluding 7/7 purged marrows
AlloBMT: allogenic bone marrow transplant
FRG: Federal Republic ofGermany
Of the nine studies of GM-CSF after bone marrow transplant with historical
controls, there was modest but statistically significantly decreased time to re-
engraftment in eight, with fewer episodes of bacteremia or organ toxicity in the
majority ofstudies. In the ninth, which used purged marrows, those patients who had
the highest levels of colony-forming units granuloyte-macrophage (CFU-GM) rein-
fused had a markedly shorter time to recovery. Dose correlated with peak WBC.
Platelets are inconsistently affected. Significant shortening of time to >500 PMNs,
>20,000 platelets, and duration ofhospitalization are reported in some series. Patient
variability appears considerably related to prior chemotherapy. Toxicity includes
myalgias, transient rash, peripheral edema, minor abdominal cramps, bone pain, and
low-grade fever. At higher doses (-30 ,.tg/kg/day), a capillary leak syndrome with
pleural and pericardial effusions becomes dose-limiting.
There are three studies of GM-CSF used in patients with poor graft function after
autologous or allogeneic bone marrow. One-half to two-thirds of patients are reported
to benefit from GM-CSF. Noteworthy again was the poor response of patients who
received purged marrow.
There are two randomized placebo-controlled trials ofGM-CSF after bone marrow
transplant. While the study from Seattle shows no significant difference in duration of
neutropenia, the number of the infectious complications and hospital days were
significantly decreased in the arm receiving GM-CSF. Fewer trials have studied
G-CSF after transplant, but more rapid engraftment in these trials has been reported
as well. One patient received G-CSF for poorgraft function. Theonly randomized trial
reports a significantly shorter period ofneutropenia in the group receiving G-CSF but
does not provide the actual days ofneutropenia.
Butturini and colleagues in Brazil used GM-CSF in eight patients suffering from
serious radioactive cesium overdose after an abandoned therapeutic radiotherapy
source was inadvertently opened by curiousvillagers, exposing many in thecommunity
[121].
PERIPHERAL BLOOD PROGENITOR CELLS (PBPC)
Preclinical Studies
There is no clear understanding ofwhy peripheral blood contains progenitor cells or
ofthe regulation ofprogenitor cell number. The circulating progenitor cell population
isapparently quite immaturecompared to marrow cells, is in Go (not in cell cycle), and
does not actively contribute to hematopoiesis. Stem cells collected from the
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peripheral blood oflaboratory animals by cytapheresis have successfully reconstituted
myelopoiesis following marrow lethal treatment [122,123].
Clinical Studies
Weiner et al. demonstrated that human PBPC could be collected via established
techniques for harvesting platelets [123]. Between five and eight leukophereses are
required for adequate stem cell collection in humans [124,125]. Methods ofcollection
using density gradient, counterflow centrifugation (surge), or methods to collect
granulocytes and mononuclear cells could influence the duration ofaplasia [126].
Initially, studies ofpatients with chronic myelogenous leukemia (CML) determined
thattheir bloodcontains anorderofmagnitude moregranulocyte-macrophage commit-
ted colony-forming units (CFU-GM) than that of normal individuals. Goldman
demonstrated engraftment after delivery of autologous PBPC collected in CML
patients by demonstrating a return to the chronic phase ofdisease [125].
Juttner et al. (Adelaide, Australia) reported good early engraftment in four AML
patients receiving PBPC collected after induction [124]. Late poor bone marrow
function developed prior to relapse of AML in three, but did not occur in the fourth
patient, who received four times the number of nucleated cells. Engraftment in AML
required significantly more progenitor cells than in non-AML malignancies [127].
Kessinger and colleagues have refined the technical collection of PBPCs and
documented successful engraftment in 34 breast cancer and Hodgkin's diseasepatients
treated with cyclophosphamide, total body irradiation, and cisplatin [128].
Adequacy and speed of recovery appears related in part to the number of stem cell
dose reinfused [28,29]. Although the actual pluripotent stem cell cannot be measured
in humans, reinfusion of >4 x 105 CFU-GM/kg body weight (15- to 50-fold that
required for ABMT recovery) results in reliable reconstitution. While lowerdoses yield
less consistent engraftment, variable results may in part result from institutional
differences in colony assay techniques and reagents. The larger number of CFU-GM
required for PBPC compared to ABMT may reflect a lower ratio of pleuripotent to
committed stem cells in peripheral blood or to the few stromal cells transplanted.
Hematopoietic reconstitution using PBPC has been reviewed in leukemia, lymphoma,
and various solid tumors [129,130].
AdvantagesofPBPCcompared to ABMT: PBPC appear to be a reliable sourceof
stem cells for reconstitution of myelopoietic function, although the concentration of
hematopoietic progenitor cells in the blood is 10- to 100-fold less than in the bone
marrow. The concentration of true "stem" cells is not measurable in the human
(because of lack of an assay), but it is common practice to measure the number of
progenitor cells committed to myeloid (granulocyte/monocyte) and to erythroid
maturation (measured as CFU-GM and BFU-E, respectively). Preliminary data
suggest that the presence of a neoplasm may increase the number of circulating
CFU-GM [131].
1. Leukapheresis is an outpatient procedure similar to platelet donation. Marrow
donation currently involves hospitalization, general anesthesia, and aspiration of
500-1,000 ml ofmarrow from pelvic bones.
2. Using the apheresis technique, adequate numbers of stem cells may be
collected from patients with hemipelvectomies, tumor involving the pelvic bones, or
after pelvic irradiation.
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3. Granulocyte reconstitution may be faster, possibly due to reinfusion oflarger
number ofcommitted mononuclear cells.
4. Recovery of immune function appears faster and more complete, possibly due
to increased numbers ofreinfused lymphocytes.
5. A consistent feature of PBPC compared with bone marrow transplants has
been rapid granulocyte reconstitution (10-16 days to >500,ul) and equivalent rates of
platelet recovery (19-25 days).
Methods ofincreasing CFU-GMyields during leukopheresis: Previous efforts to
augment circulating progenitor cell numbers have had limited success. Richman et al.
[132] first observed that nine of 14 patients given cyclophosphamide and doxorubicin
had a significantly increased concentration ofperipheral blood CFU-GM at the timeof
leukocyte recovery. Initial depletion ofthe peripheral blood CFU-GM was followed by
a rebound of up to 20-fold (median, four- to sevenfold) the baseline level. This
phenomenon has been confirmed in the majorityofpatientsreceivingchemotherapyfor
lung, ovary, breast, and other solid tumors [133,134,135,136] or following induction
chemotherapy of acute myelogenous leukemia, with leukopheresis yielding 11 ± 2 x
104 CFU-GM/kg/leukopheresis. Other methods have included dextran, steroids, and
endotoxin [129,130]. Nonetheless, between seven and ten leukophereses are required
for adequate stem cell collection; however, -8 leukophereses required per patient
strains blood bank and cryopreservation resources and delays therapy for three weeks.
Thus PBPC reinfusion is not practical as a routine source of stem cells. One interesting
technique currently under investigation is positively to select CD34 cells, using
monoclonal antibody bound to the inner surface ofa collecting device [137].
Data from Milan suggest that the combination of both bone marrow and PBPCs
collected via two to three apheresis during rebound from cyclophosphamide results in
significant shorter times to granulocyte recovery >500/gil (a median ofeight days in a
small pilot study) in patients with breast cancer or NHL [138,139,140,141].
Effect of GM-CSF on PBPC: Of 12 patients studied during three- to seven-day
continuous infusions ofGM-CSF at doses of4, 8, 16, and 64,g/kg/day [65], Socinski
et al. reported that nine had significantly increased absolute numbers of peripheral
blood CFU-GM (median, 18-fold; range, 2-200; p = 0.01). BFU-E increased a
median of eightfold. In the same patients, they observed a ten- to 100-fold increase in
circulating CFU-GM after treatment with chemotherapy and GM-CSF. Immediately
following chemotherapy, circulating CFU-GM were undectable. CFU-GM recovery
after cycle 1 increased 30-fold (14-fold for BFU-E) compared to recovery aftercycle 2
(p = .001). The peak levels ofperipheral blood CFU-GM occurred earlier in thecycle
with GM-CSF than in the cycle without GM-CSF (day 16, 16, 16 versus day 19, 22,
27). CFU-GM were increased 9- to 14-fold by the combination ofpost-chemotherapy
rebound and GM-CSF compared with GM-CSF alone. In the bone marrow, however,
CFU-GM and BFU-E did not change significantly in number [142]. In Japan, Toki et
al. have evaluated G-CSF after cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) in four lymphoma patients. The number of peripheral blood
progenitor cells increased 37- to 221-fold over baseline and peaked about day 10 [87].
Duhrsen et al. have also shown a similar effect with G-CSF [143]. (Refer to Table 9.)
Augmentation of peripheral blood progenitor cells by GM-CSF may facilitate
collection of adequate numbers of PBPC with fewer leukophereses enhancing the
feasibility of PBPC autografting. Ifeight to 12 leukapheresis sessions are required to
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TABLE 9
G- or GM-CSF Alone and with Chemotherapy: Effect on Numbers ofPeripheral Blood Progenitor Cells
Cycle 0 Cycle 1 Cycle 2
Factor Day 1 End +GM-CSF -GM-CSF
PB CFU-GM/ml 36 469 2,251 74
PB BFU-E/ml 68 242 1,125 80
Socinski et al. (142]
CFU-GM/ml
Patient
No. Day 1 Peak (Day 10) -Fold Increase
1 22 1,584 72
2 1 106 106
3 10 370 37
4 8 1,771 221
Toki et al. [87]
obtain sufficient progenitor cells, then PBPC autografting is unlikely to replace
marrow harvesting, except in special situations (e.g., known tumor involvement of the
marrow); however, the use of GM-CSF with chemotherapy ± growth factor to
augment progenitor cell number prior to pheresis theoretically could reduce the
number of required phereses (and aliquots frozen) to one to two per patient. If that
method weresuccessful, a shorter duration ofaplasia resulting from theuseofPBPC or
both PBPC and marrow maysignificantly reducethemortality, morbidity, and thecost
of high-dose therapy. Multiple groups are now testing the premise that GM-CSF can
enhance collection ofperipheral blood progenitor cells [138,140,144,145].
ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND
AIDS-RELATED COMPLEX
A 14-day iv infusion of rhGM-CSF (Sandoz) in 16 patients resulted in a dose-
dependent increase in circulating leukocytes [146]. The peak WBC ranged from 4,575
at the lowest dose, to 48,700/,ul at the highest dose. Increased circulating neutrophils,
eosinophils, and monocytes occurred in all but one patient. In three patients, the
increased circulating WBC observed during iv and three times daily subcutaneous
administration ofthe same total daily dose was comparable.
Toxicity consisted of flushing during bolus infusions at higher doses, and fever,
myalgia, and phlebitis at the peripheral iv administration site during the continuous
infusion in some patients. Three patients developed a localized, macular skin rash
lasting < 24 hours without relation to dose, duration oftreatment, or change in WBC.
Four patients with subclinical disseminated or pulmonary infection (cytomegalovirus,
M. avium complex, Pneumocystis carinii) prior to treatment with rhGM-CSF devel-
oped inflammatory symptoms during treatment. A fifth patient developed fever and
abnormal liver chemistries without any evident infectious agent. Of the five patients
with significant symptoms, three had received 8,ug/kg/day ofglycoprotein, suggesting
that this amount may be the maximum tolerated dose in this patient group when
GM-CSF is administered as a daily 24-hour iv infusion. No dose-limiting local or
systemic toxicity was encountered in three patients who received a second course
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TABLE 10
CSF Studies in AIDS
Author/Institution Responses Reference
Laboratory
Donahue GM-CSF induces proliferation ofPMN in AIDS patients [147]
Bhalla GM-CSF corrects AZT-mediated myelosuppression [148]
Perno (NCI) GM-CSF potentiates HIV viral production and AZT effect [149]
Nimer HTLV I or II infected T cells constitutively express GM-CSF [150]
=- ?leukemia
Ganser CFU-GM from AIDS patients require ft concentration GM- [151]
CSF for maximal growth
Author Institution Product No. Dose/Day Comments Reference
Groopman NEDH Sandoz 16 1.3-20 x 103 u/kg GM-CSF improves WBC [146]
NCI: National Cancer Institute
NEDH: New England Deaconess Hospital
subcutaneously three tiines daily (1, 2, and 4 ,ug/kg/day of glycoprotein). (Refer to
Table 10.)
MISCELLANEOUS OBSERVATIONS
There are a number ofobservations ofthe effects ofG- or GM-CSF in other disease
states. Urine levels of GM-CSF from patients with bilharziasis are almost twofold
higher than normals [152]. Nimer and associates at the University ofCalifornia, Los
Angeles, found that serum cholesterol levels declined significantly in eight patients
treated with GM-CSF [153].
SUMMARY
In conclusion, growth factors appear likely to enhance the recovery and function of
circulating white cells after standard-dose cancer therapy or high-dose cancer therapy
with marrow transplant and to restore leukocyte numbers and competence in the
acquired immunedeficiency syndromes and myelodysplastic syndromes. Phase I and II
trials in patients with AIDS, cancer, myeloproliferative diseases, and after bone
marrow transplant have been published. The results of phase III studies are just
becoming available. A randomized trial of G-CSF in small-cell lung cancer demon-
strates a decreased incidence of febrile neutropenia, antibiotic days, and in-hospital
days [83]. Because of the crossover design of the study, they could not address any
differences in complete response rate or survival. In a randomized trial ofGM-CSF in
patients receiving ABMT for lymphoma, there was a significantly shorter duration of
time to re-engraftment (an absolute neutrophil count of >100/,Al), number of antibi-
otic days, and time to discharge. Whether the decreased incidence offebrile neutrope-
nia or numberofantibiotic days results from earliergranulocyte recovery or from more
functionally efficient neutrophils is at present impossible to assess.
The use of G- and GM-CSF in myelodysplasia and in leukemias requires caution
prior to the availabilty of data from large randomized trials. Preliminary data from
small randomized trials suggest that the incidence ofevolution to leukemia in patients
with myelodysplasia and the number of patients with regrowth of leukemia after
induction treatment in relapsed patients with AML is not significantly different.
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Various neutropenias (idiopathic, cyclic, and congenital) seem responsive to growth
factors. Patients treated for three to 15 months continue to respond with significantly
increased granulocytes and resolution of prior infection. The subcutaneous route of
administration is convenient, and patients seem to accept it about as well as diabetics
accept insulin injections.
Because the cost of G- and GM-CSF has not become available, it is difficult to
determine at what level thesedrugs will becost-effective. They may be cost-effective in
the setting of intensive therapy such as bone marrow transplantation, where the
reliable recoveryofpatients even a fewdaysearlierwould saveseveral thousanddollars
per patient. In standard-dose therapy for regimens where the incidence ofhospitaliza-
tion for fever and neutopenia is low, there may be littlediscernable cost benefit.
Thus, so far the data suggest that growth factors will be a significant addition to the
clinician's armamentarium. In addition, they provide laboratory researchers with new
tools for examining the process ofhematopoiesis, clinically and at the molecular level.
APPENDIX 1
Abbreviations: AA: aplastic anemia ABMT: autologous bone marrow transplant ADR: adriamycin
AIDS: acquired immune deficiency syndrome Allo BMT: allogeneic bone marrow transplant AML:
acute myelocytic leukemia ANC: absolute neutrophil count APML: acute promyelocytic leukemia
BFU-E: blast-forming units erythrocytes BWH: Brigham and Women's Hospital CBDCA: carboplat-
in CFU-GM: colony-forming units granulocyte-macrophage CGL: chronic granulocytic leukemia
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone CML: chronic myelocytic
leukemia CPA: cyclophosphamide CR: complete response DDP: cisplatin DFCI: Dana-Farber Can-
cer Institute DTIC: dacarbazine FRG: Federal Republic of Germany G-CSF: granulocyte colony-
stimulating factor GM-CSF: granulocyte-macrophage colony-stimulating factor GVHD: graft-versus-
host disease HDCPA: high-dose cyclophosphamide IF: interferon Ifos: ifosfamide IL-1: interleukin
1 iv: intravenous JCF: Japan Cancer Foundation M-CSF: monocyte colony-stimulating factor
MDAH: M.D. Anderson Hospital, Houston MSKCC: Memorial Sloan-Kettering Cancer Center, New
York City N Shore: North Shore Hospital, New York NCC: National Cancer Center NEDH: New
England Deaconess Hospital NYU: New York University, New York City PBPC: peripheral blood
progenitor cells PMN: polymorphonuclear leucocyte rh: recombinant human TNF: tumor necrosis
factor UCLA: University ofCalifornia, Los Angeles VBL: vinblastine VDS: vindesine VP-16: etop-
oside WBC: white blood cell (count)
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